Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Osimertinib + Ipilimumab in EGFR-Mutated NSCLC
NCT04141644Phase 1Active, not recruiting
- Sponsor
- University of Utah
- Start
- Aug 2020
- Primary completion
- Jan 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ipilimumab in non-small cell lung cancer (NSCLC), sponsored by University of Utah. Primary endpoint: Adverse Events. Started Aug 2020; status: active, not recruiting.
02
Drugs
ipilimumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04141644.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04141644.